drugset / Trial / NCT02513238

Mesenchymal Stemcells for Radiation Induced Xerostomia

NCT02513238

Phase 2 Completed 30 enrolled Rigshospitalet, Denmark
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The current study aims to assess the safety and feasibility of the injection of autologous adipost tissue derived MSCs on radiation-induced salivary gland hypofunction and xerostomia in head and neck cancer participants. The project can potentially help to develop a clinically relevant treatment option for the growing number of patients suffering from xerostomia after radiotherapy. The development of new therapies is especially important, since only sub-optimal symptomatic treatments are currently available and the symptom of xerostomia greatly reduces the quality of life.

Timeline

Start
2015-08-08
Primary completion
2017-04-06
Completion
2017-04-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mesenchymal stem cell Cell therapy 4.6e+07 cells Other

Indications

No indication recorded.